Pancreatic Cancer Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Pancreatic Cancer Therapeutics Market: Treatment Type (Chemotherapy, Targeted therapy, Others), Disease Type (Exocrine pancreas cancer, Exocrine pancreas cancer), Distribution Channel (Hospital pharmacies, Retail Pharmacies, Online pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Pancreatic Cancer Therapeutics Market size was valued at USD 3,834 million in 2021 and is expected to reach USD 6,787.6 million by 2028, at a CAGR of 8.5% during the forecast period 2022 to 2028.  Pancreatic cancer is the disease characterized by the abnormal proliferation of tumor cells in the pancreas leads to hinder in the pancreas function. Pancreatic cancer is majorly classified into 2 types namely exocrine cancers and neuroendocrine cancers. Symptoms associated with the pancreas cancer include jaundice, weight loss, abdominal pain, and diarrhea. Pancreatic cancer mainly occurs due to the consumption of tobacco and alcohol, smoking, obesity, and family history of pancreatitis. Pancreatic cancer can be diagnosed by using the MRI, CT scan, and ultrasound techniques and can be prevented by chemotherapy, radiotherapy, and surgery. Global Pancreatic Cancer Therapeutics Market is growing at a significant CAGR owing to increase in the prevalence of pancreatic cancer and increase in R&D activities for the innovation of newer therapeutics. Increase in the government funding and huge investments from the private sector for R&D activities is anticipated to propel the market growth. Acquisitions & mergers, collaborations, product pipeline are the key factors driving the market players revenue growth inGlobal Pancreatic Cancer Therapeutics Market. For instance, in December 2015, Boehringer Ingelheim collaborated with MD Andersen Cancer Centre for the development of newer therapeutics for pancreatic cancer. Similarly, in September 2013, Celgene received FDA approval for Abraxane used for the treatment of pancreatic cancer.

Pancreatic Cancer Therapeutics Market

MARKET SUMMARY
-
8.5%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 8.5%
  • Largest Market– North-America
  • Fastest Growing Market– Asia-Pacific

Pancreatic Cancer Therapeutics Market

  • The pancreatic cancer therapeutics market report gives comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global pancreatic cancer therapeutics market gives historical, current, and future market sizes (US$ Mn) on the basis of disease type, treatment type, end user and region.
Key Players
  • F. Hoffmann-La Roche Ltd. (Switzerland),
  • Novartis AG (Switzerland),
  • Merck & Co., Inc. (U.S.),
  • Pfizer, Inc. (U.S.),
  • Eli Lilly and Company (U.S.),
  • Boehringer Ingelheim GmbH (Germany),
  • Celgene Corporation (U.S.),
  • Amgen, Inc. (U.S.),
  • Ipsen (France)

 

Pancreatic Cancer Therapeutics Market

DRIVERS AND RESTRAINTS

Increase in the alcohol and tobacco consumption, a rise in the government funding for the R&D activities, growing prevalence of pancreatic cancer diseases, and promising pipeline drugs for the pancreatic cancer treatment are anticipated to propel the pancreatic cancers market growth over the forecast period. Furthermore, rise in obesity population, family history of pancreatitis, huge investment by the companies for the development of newer drugs expected to drive the Global Pancreatic Cancer Therapeutics Market over the forecast period. However, stringent regulatory policies, difficulty in early-stage disease diagnosis, the high cost of the treatment, adverse effects associated with the drugs, and lesser drugs available for the treatment might hamper the growth of Global Pancreatic Cancer Therapeutics Market.


North-America Got Significant Share

Pancreatic Cancer Therapeutics Market

Geographically, Global Pancreatic Cancer Therapeutics Market is segmented into the Europe, Latin America, Asia Pacific, the Middle East and Africa, and North America. North America pancreatic cancer therapeutics market is growing at a significant rate due to increase in the prevalence of pancreatic cancer majorly in U.S. (according to NIH 2014, about 64,668 people diagnosed with pancreatic cancer). In addition, high adoption of pancreatic therapeutics, increase in healthcare expenditure, and rise in R&D activities are propelling the pancreatic cancer therapeutics market in North America. In Europe region, rise in the prevalence of pancreatic cancer majorly in Germany, Finland, Austria, U.K and other Europe countries (according to Cancer Research UK 2014, about 9,600 new pancreatic cancer cases in the UK and 8,817 people died of the disease), and developed healthcare infrastructure boost the Global Pancreatic Cancer Therapeutics Market. However, Asia Pacific is an emerging region for pancreatic cancer therapeutics market owing to increase in R&D expenditure rise in geriatric and obese population, growing healthcare expenditure are expected to fuel the market over the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Findings of the Report

  • The report provides granular level information about the market size, regional market share, and forecast from 2022-2028
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Pancreatic Cancer Therapeutics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Pfizer, Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Celgene Corporation (U.S.)
  • Amgen, Inc. (U.S.)
  • Tempus, Inc. (U.S.)
  • Ipsen (France)

Description

Pancreatic Cancer Therapeutics Market size was valued at USD 3,834 million in 2021 and is expected to reach USD 6,787.6 million by 2028, at a CAGR of 8.5% during the forecast period 2022 to 2028.  Pancreatic cancer is the disease characterized by the abnormal proliferation of tumor cells in the pancreas leads to hinder in the pancreas function. Pancreatic cancer is majorly classified into 2 types namely exocrine cancers and neuroendocrine cancers. Symptoms associated with the pancreas cancer include jaundice, weight loss, abdominal pain, and diarrhea. Pancreatic cancer mainly occurs due to the consumption of tobacco and alcohol, smoking, obesity, and family history of pancreatitis. Pancreatic cancer can be diagnosed by using the MRI, CT scan, and ultrasound techniques and can be prevented by chemotherapy, radiotherapy, and surgery. Global Pancreatic Cancer Therapeutics Market is growing at a significant CAGR owing to increase in the prevalence of pancreatic cancer and increase in R&D activities for the innovation of newer therapeutics. Increase in the government funding and huge investments from the private sector for R&D activities is anticipated to propel the market growth. Acquisitions & mergers, collaborations, product pipeline are the key factors driving the market players revenue growth inGlobal Pancreatic Cancer Therapeutics Market. For instance, in December 2015, Boehringer Ingelheim collaborated with MD Andersen Cancer Centre for the development of newer therapeutics for pancreatic cancer. Similarly, in September 2013, Celgene received FDA approval for Abraxane used for the treatment of pancreatic cancer.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX